Monitor proxy vote outcome closely; if the Radoff-JEC Group wins at least one board seat, expect accelerated strategic review or sale process. The activist's prior acquisition proposals suggest a floor near $2.40/share. Key catalyst is the July 28 annual meeting — position for potential premium realization if activist gains traction.
Price Chart
Executive Summary
The Radoff-JEC Group (7.7% owner) filed a definitive additional proxy statement (DFAN14A) attacking Seer's CEO and board for 97% stock decline since IPO, seeking to elect three director nominees at the July 28, 2026 annual meeting. The group previously made three acquisition proposals (latest $2.40/share + CVR, 42% premium) that were rejected. This escalation in the proxy fight increases pressure on management to consider strategic alternatives.
Key Financial Metrics
Key Facts
- Radoff-JEC Group owns ~7.7% of Seer outstanding shares
- Seeking election of three independent director nominees: Howard H. Berman, Joshua S. Horowitz, Luis E. Rinaldini
- Annual meeting scheduled for July 28, 2026
- Stock down 97% since December 2020 IPO
- CEO Omid Farokhzad's prior companies include BIND Therapeutics (bankruptcy), Selecta Biosciences (-93.7%), Tarveda Therapeutics (liquidation), Senti Biosciences (-98.5%)
- Group made three non-binding acquisition proposals (latest $2.40/share + CVR) rejected by board without engagement
- Board adopted poison pill after 13D filing
Financial Impact
Potential for significant stock re-rating if activist wins board seats, with prior acquisition proposal at $2.40/share (42% premium to pre-proposal price) plus contingent value rights. Current market cap ~$95M vs $219.5M cash on balance sheet.
Risk Factors
- Management may retain control due to poison pill and entrenched board
- Low probability of activist winning all three seats given small stake (7.7%)
- Stock could decline further if activist fails and no strategic changes occur
- CEO's track record suggests continued value destruction if no change
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DFAN14A Filing (Primary) | 0000921895-26-001611 |
| Document: 0000921895-26-001611-index-headers.html | 0000921895-26-001611 |
| Document: 0000921895-26-001611-index.html | 0000921895-26-001611 |
| Document: 0000921895-26-001611.txt | 0000921895-26-001611 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | Press Release | $1.97 | awaiting T+20 | — | $1.97 (−0.25%) |
Oct 15, 2026 12d ago | ITC Section 337 | $2.03 | awaiting T+20 | — | $1.97 (−3.20%) |
Oct 8, 2026 18d ago | 3 | $2.19 | awaiting T+20 | — | $1.97 (−10.27%) |
Sep 21, 2026 5w ago | Press Release | $1.86 $2.02 | ▲ +8.60% | ▲ +9.51% | $1.97 (+5.65%) |
Jul 31, 2026 12w ago | 8-K | $2.22 $1.98 | ▼ −10.81% | ▼ −13.80% | $1.97 (−11.49%) |
Jul 28, 2026 12w ago | Press Release | $2.08 $2.02 | ▲ +2.88% | ▲ +7.90% | $1.97 (+5.53%) |
Jul 28, 2026 12w ago | DFAN14A | $2.14 $2.04 | ▼ −4.67% | ▼ −8.05% | $1.97 (−8.18%) |
Jul 20, 2026 14w ago | DEFA14A | $2.04 $2.03 | ▼ −0.49% | ▼ −4.61% | $1.97 (−3.68%) |
Jul 20, 2026 14w ago | Press Release | $2.04 $2.03 | ▼ −0.49% | ▼ −4.61% | $1.97 (−3.68%) |
Jul 8, 2026 15w ago | DEFA14A | $2.18 $2.19 | ▲ +0.46% | ▼ −2.81% | $1.97 (−9.86%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers